FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160630814> ?p ?o ?g. }

• W2160630814 endingPage "42" @default.
• W2160630814 startingPage "36" @default.
• W2160630814 abstract "Most patients with advanced prostate cancer after prostate-specific antigen (PSA) relapse following maximum androgen blockade rapidly progress to death. The present study was aimed to predict the survival of these serious patients after PSA relapse. Sixty-eight patients with M1b and 20 patients with T3b, who relapsed and died of cancer within a short period, were studied. PSA-doubling time (PSA-DT) at PSA relapse influenced the outcome after PSA relapse [hazard ratio (CI): 2.000 (1.283–3.226)]; thus, on the basis of the median values of PSA-DT (>2 months) and additionally nadir PSA in previous treatment (≤2 ng/ml), patients were stratified into four groups. Outcome in the respective groups was examined. The patients with PSA-DT of >2 months and nadir PSA of ≤2 ng/ml showed the longest survival. The other patients in various classifications proceeded with the similarly worse outcomes, in which PSA-DT still influenced survival [hazard ratio (CI): 0.422 (0.203–0.878)]. In several treatments, estramustine phosphate and dexamethasone were relatively effective. A similar rate of response to these drugs was obtained in all four groups, irrespective of stratifying with PSA-DT and nadir PSA, and this may be possibly due to the intervals between relapse and treatments, in which tumor volume was increased and tumor property was altered. Patients responding to treatment showed prolonged survival. Both PSA-DT and nadir PSA were predictive factors for subsequent survival at PSA relapse, and the patients with long PSA-DT and low nadir PSA may show long outcome." @default.
• W2160630814 created "2016-06-24" @default.
• W2160630814 creator A5003269233 @default.
• W2160630814 creator A5006184767 @default.
• W2160630814 creator A5050057887 @default.
• W2160630814 creator A5053220458 @default.
• W2160630814 creator A5053794454 @default.
• W2160630814 creator A5054015349 @default.
• W2160630814 date "2008-01-01" @default.
• W2160630814 modified "2023-10-18" @default.
• W2160630814 title "Outcome of Patients with Hormone-Refractory Prostate Cancer: Prognostic Significance of Prostate-Specific Antigen-Doubling Time and Nadir Prostate-Specific Antigen" @default.
• W2160630814 cites W1574276746 @default.
• W2160630814 cites W1907260682 @default.
• W2160630814 cites W1969753482 @default.
• W2160630814 cites W1971336398 @default.
• W2160630814 cites W1977315722 @default.
• W2160630814 cites W1977689836 @default.
• W2160630814 cites W1978764883 @default.
• W2160630814 cites W1981178948 @default.
• W2160630814 cites W1995284087 @default.
• W2160630814 cites W2012703849 @default.
• W2160630814 cites W2016042280 @default.
• W2160630814 cites W2016631360 @default.
• W2160630814 cites W2024404898 @default.
• W2160630814 cites W2041896886 @default.
• W2160630814 cites W2042094121 @default.
• W2160630814 cites W2043731907 @default.
• W2160630814 cites W2050137994 @default.
• W2160630814 cites W2053306253 @default.
• W2160630814 cites W2060308596 @default.
• W2160630814 cites W2060787452 @default.
• W2160630814 cites W2071503820 @default.
• W2160630814 cites W2071666116 @default.
• W2160630814 cites W2071932144 @default.
• W2160630814 cites W2072673199 @default.
• W2160630814 cites W2075539488 @default.
• W2160630814 cites W2078814775 @default.
• W2160630814 cites W2081737582 @default.
• W2160630814 cites W2082677806 @default.
• W2160630814 cites W2095346513 @default.
• W2160630814 cites W2103090668 @default.
• W2160630814 cites W2114608969 @default.
• W2160630814 cites W2117296712 @default.
• W2160630814 cites W2120178936 @default.
• W2160630814 cites W2125344257 @default.
• W2160630814 cites W2132315278 @default.
• W2160630814 cites W2134280954 @default.
• W2160630814 cites W2137987387 @default.
• W2160630814 cites W2143231879 @default.
• W2160630814 cites W2150669112 @default.
• W2160630814 cites W2151114651 @default.
• W2160630814 cites W2155679349 @default.
• W2160630814 cites W2160316498 @default.
• W2160630814 cites W2165564512 @default.
• W2160630814 cites W2167869791 @default.
• W2160630814 cites W2440063679 @default.
• W2160630814 cites W96401522 @default.
• W2160630814 doi "https://doi.org/10.1093/jjco/hym153" @default.
• W2160630814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18258713" @default.
• W2160630814 hasPublicationYear "2008" @default.
• W2160630814 type Work @default.
• W2160630814 sameAs 2160630814 @default.
• W2160630814 citedByCount "10" @default.
• W2160630814 countsByYear W21606308142012 @default.
• W2160630814 countsByYear W21606308142017 @default.
• W2160630814 countsByYear W21606308142022 @default.
• W2160630814 crossrefType "journal-article" @default.
• W2160630814 hasAuthorship W2160630814A5003269233 @default.
• W2160630814 hasAuthorship W2160630814A5006184767 @default.
• W2160630814 hasAuthorship W2160630814A5050057887 @default.
• W2160630814 hasAuthorship W2160630814A5053220458 @default.
• W2160630814 hasAuthorship W2160630814A5053794454 @default.
• W2160630814 hasAuthorship W2160630814A5054015349 @default.
• W2160630814 hasBestOaLocation W21606308141 @default.
• W2160630814 hasConcept C121608353 @default.
• W2160630814 hasConcept C126322002 @default.
• W2160630814 hasConcept C126894567 @default.
• W2160630814 hasConcept C127413603 @default.
• W2160630814 hasConcept C143998085 @default.
• W2160630814 hasConcept C146978453 @default.
• W2160630814 hasConcept C19269812 @default.
• W2160630814 hasConcept C207103383 @default.
• W2160630814 hasConcept C2776235491 @default.
• W2160630814 hasConcept C2780192828 @default.
• W2160630814 hasConcept C2781406297 @default.
• W2160630814 hasConcept C44249647 @default.
• W2160630814 hasConcept C71924100 @default.
• W2160630814 hasConcept C88575799 @default.
• W2160630814 hasConceptScore W2160630814C121608353 @default.
• W2160630814 hasConceptScore W2160630814C126322002 @default.
• W2160630814 hasConceptScore W2160630814C126894567 @default.
• W2160630814 hasConceptScore W2160630814C127413603 @default.
• W2160630814 hasConceptScore W2160630814C143998085 @default.
• W2160630814 hasConceptScore W2160630814C146978453 @default.
• W2160630814 hasConceptScore W2160630814C19269812 @default.
• W2160630814 hasConceptScore W2160630814C207103383 @default.
• W2160630814 hasConceptScore W2160630814C2776235491 @default.
• W2160630814 hasConceptScore W2160630814C2780192828 @default.

• next